Patients initiated treatment with placebo or REQUIP XL at 2 mg/day for 1 week and were either maintained at a target dose of 2 mg/day or further increased to a target dose of 4, 8, 12, or 24 mg/day over a 13-week up-titration period. ), les allergies, les maladies préexistantes, et les conditions de santé actuel (par exemple la grossesse, une chirurgie prochaine, etc.). In patients who reduced their L-dopa dose, reduction was sustained in 93% of patients treated with REQUIP XL and in 72% of patients treated with placebo (A double-blind, placebo-controlled, fixed-dose, parallel-group trial evaluated the dose response of REQUIP XL as adjunctive therapy to L-dopa in 352 randomized patients with advanced Parkinson’s disease (Hoehn & Yahr criteria Stages II-IV) over a total dosing period of 18 weeks. Available for Android and iOS devices. Some have reported these events more than 1 year after initiation of treatment.Among the 613 patients who received REQUIP XL in flexible-dose clinical trials (Study 1 and Study 3), <1% of patients reported sudden onset of sleep and <1% of patients reported a motor vehicle accident in which it is not known if falling asleep was a contributing factor.In a placebo-controlled fixed-dose trial in patients with advanced Parkinson’s disease (Study 2), sudden onset of sleep was reported in 4% of 276 patients on REQUIP XL compared with 3% of 74 patients on placebo. After 2 days, if necessary, the dose can be increased to 0.5 mg once daily, and to 1 mg once daily at the end of the first week of dosing, then as shown in Table 2 as needed to achieve efficacy. For more information go to www.gsk.com or call 1-888-825-5249 (toll-free).Trademarks are owned by or licensed to the GSK group of companies.This Patient Information has been approved by the U.S. Food and Drug AdministrationEach tablet contains 2.28 mg ropinirole HCl equivalent to 2 mg ropinirole. (See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.REQUIP XL is indicated for the treatment of Parkinson’s disease.The recommended starting dose of REQUIP XL is 2 mg taken once daily for 1 to 2 weeks, followed by increases of 2 mg/day at weekly or longer intervals, based on therapeutic response and tolerability. Monitor patients at least weekly during dose titration. Patients treated with REQUIP XL had a mean reduction in L-dopa dose of 278 mg/day (34%), while patients treated with placebo had a mean reduction of 164 mg/day (21%). The primary efficacy endpoint was the mean change from baseline in total awake time spent “off” at Week 4 of the maintenance period with daily doses of 4, 8, 12, 16, and 24 mg compared with placebo. Therefore, if therapy with a drug known to be a potent inducer or inhibitor of CYP1A2 is stopped or started during treatment with REQUIP XL, adjustment of the dose of REQUIP XL may be required. The primary statistical analysis of the primary efficacy endpoint was Mixed Model Repeated Measures (MMRM).At baseline, the mean “off” time ranged from 5.6 to 6.5 hours across groups on REQUIP XL and placebo. Ne les divisez pas, ne les mâchez pas et ne les écrasez pas. Inform patients who experience these or similar reactions after starting REQUIP or REQUIP XL, to immediately contact their healthcare professional Alert patients to the potential sedating effects caused by REQUIP XL, including somnolence and the possibility of falling asleep while engaged in activities of daily living. In pregnant rabbits, ropinirole potentiated the teratogenic effects of L-dopa when these drugs were administered in combination In the U.S. general population, the estimated background risk of major birth defects and of miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Comprimés oraux de dosage régulier: Pour la maladie de Parkinson: Adultes: Commencez avec 0, 25 mg, trois fois par jour. Too rapid a rate of titration may lead to the selection of a dose that does not provide additional benefit, but increases the risk of adverse reactions.In fixed-dose studies designed to characterize the dose response to REQUIP XL, there was no additional therapeutic benefit shown in patients with advanced stage Parkinson’s disease taking daily doses greater than 8 mg/day, or with early stage Parkinson’s disease taking doses greater than 12 mg/day REQUIP XL should be discontinued gradually over a 7-day period.No dose adjustment is necessary in patients with moderate renal impairment (creatinine clearance of 30 to 50 mL/min). Patients initiated treatment with placebo or REQUIP XL at 2 mg/day for 1 week, and increased to a target dose of 4, 8, 12, 16, or 24 mg/day over a 13-week up-titration period. If a dose is missed, advise patients not to double their next dose. This abnormal thinking and behavior can consist of one or more of a variety of manifestations including paranoid ideation, delusions, hallucinations, confusion, psychotic-like behavior, symptoms of mania (e.g., insomnia, psychomotor agitation), disorientation, aggressive behavior, agitation, and delirium.Patients with a major psychotic disorder should ordinarily not be treated with REQUIP XL because of the risk of exacerbating the psychosis.